Replies to post #170210 on Avid Bioservices Inc (CDMO)

[volgoat]

Tiger better slather up.....

PS: that is why I was so glad to see Choe and others presenting PS talks at Keystone this w/e and next week. Peer reviewed after Bavi was at Scripps for years....

[EYEBUYSTOX]

Bio, just to play devil's advocate...that's 2.3 million that some PPHM grant writer missed out on for some reason when the entire emphasis of our platform is the center of their thesis supporting the grant of $2.3 million. So, they better announce some kind of collaboration soon or, to me, it looks as though PPHM technical writers missed another opportunity to expand the platform and will ultimately cost us further dilution. Sigh.

For such an obvious and widely recognized phonomenon as ps-flipping, we sure do make monetizing it a long, painful journey.

[biopharm]

The principal investigator for the new five-year study is TSRI Associate Professor Hyeryun Choe, who will lead the effort to understand the virus's mode of infection and how new therapies might interrupt it.

"Flavivirus uses a very clever method of infection," Choe said. "It's like using a side door to enter a house when the front door is locked."

The viruses take advantage of the process that normally occurs during programmed cell death. During programmed cell death ("apoptosis"), a lipid usually found on the inner side of the cell membranes, specifically phosphatidylserine (PS), shifts to the surface, making itself readily available to any passing cellular stranger. This is where the trouble begins.

So the above news regarding Hyeryun Choe and her research that supports PS targeting in fighting viruses (including Dengue/Ebola..etc) was back on March 27, 2014 and keep in mind of the latest patent filed by Peregrine, where they focus on "phospolipids" which includes flipped PS but I guarantee there are other lipid targets they didn't want to disclose just yet.

--------------------------------

Scripps Research Institute Appoints Two Noted Harvard Scientists

Dec 13, 2012

Choe said, “I’m extremely pleased to become part of Scripps Florida. Over the years, my laboratory has been moving from basic to more translational science, and Scripps Florida has a great reputation in both. I’m looking forward to working with other scientists, particularly medicinal chemists, in developing new therapeutic approaches to viral infection.”

.....
Hyeryun Choe

Choe has focused on identifying the processes by which enveloped viruses enter their target cells. That focus has led to the identification of a number of key factors essential for entry of HIV-1, SARS coronavirus and a number of hemorrhagic fever viruses.

Among her significant research is a 2007 Nature paper that reported the identification of a key receptor for pathogenic New World arenaviruses—Machupo, Junin, Guanarito and Sabia, which cause hemorrhagic fever and significant casualties in various regions of South America. The team was also able to show that iron depletion enhances, and iron supplementation slows, infection by these viruses, suggesting iron supplement as a possible treatment.

Choe received a bachelor’s degree from Seoul National University in Korea in 1977 and a master’s degree in 1980. She was awarded a PhD from Pennsylvania State University in 1984, and subsequently conducted postdoctoral work at Harvard Medical School.

In 1997, Choe was appointed as an instructor at the Dana-Farber Cancer Institute and Harvard Medical School. In 2000, became an assistant professor at Children’s Hospital and Harvard Medical School.

Choe was the second most cited scientist for research published in 1996-7 as reported by Thomson Reuters' Essential Science Indicators Science Watch; in 2002, she was named a Prominent Scientist by the Society for Biomedical Research.

Farzan and Choe both live in Juno Beach.

http://www.scripps.edu/news/press/2012/20121213flappts.html

------------------------------------------------

Now.... pay attention closely here, because as some employees are modifying their profiles so its not as noticeable that the anti-PS platform of technologies is advancing.... there are others that are adding to their bios to include PS targeting, such as:

-----------------------------------------------

Hyeryun Choe, Ph.D.

Associate Professor
Department of Infectious Diseases
Florida Campus

Research Focus

Viruses enter cells through common underlying mechanisms. Parallel studies of the entry processes of various viruses can therefore highlight differences among them, as well as their similarities. The Choe laboratory studies a range of viruses to better understand their entry pathways and the mechanisms of pathogenesis of viral diseases. In doing so, we identified a number of host factors critical for viral infection and pathogenesis. These include: the HIV-1 coreceptor CCR5, and its post-translational modification tyrosine sulfation critical HIV-1 infection; the SARS-CoV receptor angiotensin-converting enzyme 2 (ACE2) and the lysosomal enzyme cathepsin L as an essential target-cell factors for SARS-CoV infection; transferrin receptor 1 (TfR1) as the receptor for New World hemorrhagic fever arenaviruses, and an antibody that inhibits the infection of all five pathogenic New World arenaviruses. Recently we also described how the TIM family of phosphatidylserine receptors promote infections of a wide range of enveloped viruses. We will continue our efforts to identify and characterize host factors, which modulate virus infection, and use our insight to develop protein and small molecular inhibitors of viral replication.

http://www.scripps.edu/research/infectious-diseases/faculty.html?name=choe

........ notice how she (Choe) says "an antibody" ... the mystery can only remain a mystery for so long but if you want to just look at the puzzle pieces--- didn't Choe just say on the reply post this was made from and stated: "This is where the trouble begins."

It begins and ends with PS Targeting... and I don't blame them if they want to keep it under wraps till a top notch manufacturing facility is up and running, because Bavituximab, or possibly other PS Targeting agents will be in demand, globally.

Now back to the beach and sun and waiting for the exponential run to pps of $100

[asmarterwookie]

YES YES YES biopharm.....Scripps Florida scientist awarded $2.3 million to study dengue fever and related viruses

March 27, 2014

The writing is on the wall.


Will this be the catalyst? One that is forced?

OR

Will the "treatment" be kept confidential?

Interesting times.

wook